Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC.CPRX · Entity 29708 | Chief Commercial Officer | December 02, 2019 | December 04, 2019 |
| PDS Biotechnology CorpEDGE · Entity 7939 | Chief Operating Officer | March 01, 2018 | March 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CATALYST PHARMACEUTICALS, INC.
Report date December 02, 2019 · Filed December 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2026-12-02 | Direct | 647,000 |
Reported balance
After 2019-12-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-02 · Grant · Acquired 132,000 · Balance 647,000 F1: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 691,000 |
Reported balance
After 2019-12-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-02 · Grant · Acquired 44,000 · Balance 691,000 F2: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3: Shares of common stock will be delivered to the Reporting Person upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022.
F2: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F3: Shares of common stock will be delivered to the Reporting Person upon vesting.
PDS Biotechnology Corp
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right To Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $14.98 · Expires 2028-03-01 | Direct | 90,000 |
Reported balance
After 2018-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 90,000 · Balance 90,000 F1: This option, representing a right to purchase a total of 90,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, representing a right to purchase a total of 90,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2019 Filed Dec 4, 2019 22:19 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-19-000514 · form4.xml · derivative · entry 2 BRENNAN DANIEL · CIK 0001657999 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,000 Underlying: Common Stock · 44,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:19 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 132,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001161697-19-000514 · form4.xml · derivative · entry 1 BRENNAN DANIEL · CIK 0001657999 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,000 Underlying: Common Stock · 132,000 shares Expires 2026-12-02 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:46 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 38,334 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-18-000620 · form4.xml · derivative · entry 3 BRENNAN DANIEL · CIK 0001657999 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,000 Underlying: Common Stock · 38,334 shares Expires 2025-12-19 Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:46 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 38,333 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-18-000620 · form4.xml · derivative · entry 2 BRENNAN DANIEL · CIK 0001657999 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,666 Underlying: Common Stock · 38,333 shares Expires 2025-12-19 Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:46 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 38,333 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-18-000620 · form4.xml · derivative · entry 1 BRENNAN DANIEL · CIK 0001657999 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,333 Underlying: Common Stock · 38,333 shares Expires 2025-12-19 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 13:29 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 90,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009817 · form4.xml · derivative · entry 1 BRENNAN DANIEL · CIK 0001657999 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 90,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 17:44 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (right To Purchase) · Derivative | 150,000 | $10.09 Strike: $10.09 | $1,513,500.00 |
DisclosureSEC source: 0001127602-16-065820 · form4.xml · derivative · entry 1 BRENNAN DANIEL · CIK 0001657999 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-10-31 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 150,000 shares of Common Stock, will become exercisable on October 17, 2017, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.